SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

ANG Lifesciences India informs about newspaper publication

05 Jun 2026 Evaluate
Pursuant to Regulation 30 & 47 of SEBI (Listing Obligation and Disclosure Réquirements) Regulations, 2015, ANG Lifesciences India has enclosed copies of Newspaper Advertisement of the Audited Financial Results (Standalone & Consolidated) for the Quarter & year ended on 31st March, 2026, published in the English Newspaper having nationwide circulation - Business Standard and one in Vernacular Newspaper - Aj Di Awaaz on Monday, 01 June, 2026.

The above information is a part of company’s filings submitted to BSE.  

ANG Lifesciences Share Price

32.00 -0.65 (-1.99%)
07-Jul-2026 14:18 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1906.70
Dr. Reddys Labs. 1365.05
Cipla 1457.45
Zydus Lifesciences 1155.50
Lupin 2486.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: